TuHURA Biosciences, Inc. | WebDisclosure

Basculer en Français

8295	Companies
114846	Keywords
55284	Articles
62436	Press releases

Headlines Articles Press releases TuHURA Biosciences, Inc.

Home
Companies
TuHURA Biosciences, Inc.

BRIEF

published on 10/23/2024 at 14:35, 28 days 20 hours ago

TuHURA Biosciences (Nasdaq : HURA) présente son projet au sommet virtuel Maxim Healthcare

TuHURA Biosciences Immuno-oncologie IFx-2.0 Inhibiteurs De Points De Contrôle Sommet Virtuel Maxim Healthcare
BRIEF

published on 10/23/2024 at 14:35, 28 days 20 hours ago

TuHURA Biosciences (Nasdaq: HURA) Presents at Maxim Healthcare Virtual Summit

TuHURA Biosciences Immune-oncology IFx-2.0 Checkpoint Inhibitors Maxim Healthcare Virtual Summit
PRESS RELEASE

published on 10/23/2024 at 14:30, 28 days 20 hours ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
TuHURA Biosciences, Inc. participated in the 2024 Maxim Healthcare Virtual Summit, sharing insights on overcoming resistance to cancer immunotherapy. The company is developing innovative technologies for immuno-oncology

TuHURA Biosciences Immune-oncology Resistance To Cancer Immunotherapy Novel Technologies Phase 3 Registration
BRIEF

published on 10/22/2024 at 15:05, 29 days 20 hours ago

TuHURA Biosciences s'apprête à faire une présentation lors d'un événement virtuel pour les investisseurs

TuHURA Biosciences Immuno-oncologie Événement Virtuel Pour Les Investisseurs Essais De Phase 3 Résistance Au Cancer
BRIEF

published on 10/22/2024 at 15:05, 29 days 20 hours ago

TuHURA Biosciences Set to Present at Virtual Investor Event

TuHURA Biosciences Virtual Investor Event Immune-oncology Phase 3 Trials Cancer Resistance
PRESS RELEASE

published on 10/22/2024 at 15:00, 29 days 20 hours ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
TuHURA Biosciences, Inc. to present at Virtual Investor New to the Street Event featuring Dr. Jim Bianco discussing company's outlook and technologies for cancer immunotherapy

TuHURA Biosciences Phase 3 Trial Virtual Investor Event Cancer Immunotherapy Dr. Jim Bianco
BRIEF

published on 10/17/2024 at 21:38, 1 month 3 days ago

TuHURA Biosciences and Kintara Therapeutics Complete Merger

Merger TuHURA Biosciences Phase 3 Trial Cancer Immunotherapy NASDAQ Trading
BRIEF

published on 10/17/2024 at 21:38, 1 month 3 days ago

TuHURA Biosciences et Kintara Therapeutics finalisent leur fusion

TuHURA Biosciences Fusionnement Essai De Phase 3 Immunothérapie Contre Le Cancer Négociation Sur Le Nasdaq
PRESS RELEASE

published on 10/17/2024 at 21:33, 1 month 3 days ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics
TuHURA Biosciences, Inc. completes merger with Kintara Therapeutics, focusing on cancer immunotherapy technologies. Phase 3 trial in 2025 under SPA agreement with FDA

Merger TuHURA Biosciences FDA Agreement Immunotherapy Phase 3 Trial
BRIEF

published on 08/19/2024 at 15:05, 3 months 1 day ago

Kineta Inc. rouvre les inscriptions pour l'essai clinique VISTA-101

TuHURA Biosciences Essai Clinique Oncologie KVA12123 Kineta Inc.

Accesswire

Published on 11/21/2024 at 10:03, 1 hour 24 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 27 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 27 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 52 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 11 hours 2 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:01, 26 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 27 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 30 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 57 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 1 hour 22 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 29 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 29 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 29 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 19 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 7 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE